Literature DB >> 1421872

Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.

T Kubota1, T Inada, Y Ogata.   

Abstract

To clarify the mode of antitumor activity shown by a combination of recombinant human interferon alpha-2a (IFN) and 5-fluorouracil (5-FU), experimental therapy was performed on human colon carcinoma (Co-4) xenografts serially transplanted into nude mice, using IFN and 5-FU, either alone or in combination. IFN alone showed dose-dependent antitumor activity and 5-FU also revealed a moderate antitumor effect. Although IFN, given as 600,000 units/mouse daily sc x 14, and 5-FU, given as 60 mg/kg q4d x 3 ip, showed additive antitumor activity against Co-4, the thymidylate synthetase (TS) inhibition rate was unchanged in the tumors treated with the IFN/5-FU combination in comparison with those treated with 5-FU alone. This suggests that the antitumor activity of IFN and 5-FU in combination does not involve augmentation of the TS inhibition by 5-FU.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421872     DOI: 10.1007/bf00308803

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  7 in total

1.  Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.

Authors:  L Elias; H A Crissman
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

2.  Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice.

Authors:  T Kubota; M Nakada; K Tsuyuki; T Inada; F Asanuma; K Ishibiki; O Abe
Journal:  Jpn J Cancer Res       Date:  1986-05

3.  In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.

Authors:  C P Spears; A H Shahinian; R G Moran; C Heidelberger; T H Corbett
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

4.  Pharmacodynamic aspects of in vitro and in vivo chemosensitivity tests.

Authors:  Y Isobe; T Kubota; F Asanuma; H Kurihara; T Inada; T Fukutomi; K Ishibiki; O Abe
Journal:  Jpn J Cancer Res       Date:  1987-09

5.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

Authors:  S Wadler; E L Schwartz; M Goldman; A Lyver; M Rader; M Zimmerman; L Itri; V Weinberg; P H Wiernik
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

6.  Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.

Authors:  S Wadler; R Wersto; V Weinberg; D Thompson; E L Schwartz
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

7.  Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.

Authors:  T Kubota; S Fujita; S Kodaira; T Yamamoto; K Josui; Y Arisawa; A Suto; K Ishibiki; O Abe; K Mabuchi
Journal:  Jpn J Cancer Res       Date:  1991-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.